Skip to main content
. Author manuscript; available in PMC: 2014 Jan 28.
Published in final edited form as: Cancer Lett. 2012 Oct 9;328(2):307–317. doi: 10.1016/j.canlet.2012.10.001

Figure 2. The effect of nilotinib on ABCB1 xenograft models.

Figure 2

Potentiation of antitumor effects of paclitaxel by nilotinib in ABCB1 overexpressing (KB-C2) oral epidermoid carcinoma xenograft model is shown. Atleast two independent experiments were carried out using athymic NCR nude mice implanted s.c. with KB-C2 cells. A. A representative picture of the excised KB-C2 tumor sizes from different mice is shown on the 18th day after implantation. B. The bar graph represents the mean tumor weight (n=6-10) of the excised KB-C2 tumor from different mice. The treatments were as follows: (a) vehicle (q3d × 6), (b) paclitaxel (18 mg/kg, i.p., q3d × 6) (c) nilotinib (75 mg/kg, p.o., q3d × 6) (d) paclitaxel (18 mg/kg, i.p., q3d × 6) + nilotinib (75 mg/kg, p.o., q3d × 6, given 1 h before giving paclitaxel). Each column represent the mean determinations and the bars represent SD. *, P < 0.05; **, P < 0.001 versus the control group. C. Changes in mean body weight before and after treatment for ABCB1-xenograft model are shown in the bar graph. D. Changes in tumor volume with time in ABCB1-xenograft model are shown. Points represent mean tumor volume for each group (n=6) after implantation. Each point on line graph represent the mean tumor volume (mm3) at a particular day after implantation and the bars represent SD. *, P < 0.05 versus the vehicle group; *,#, P < 0.05 versus paclitaxel alone group.